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Abstract: Travelers’ diarrhea is a common illness among international travelers from developed 
to developing countries. Travelers’ diarrhea is caused by ingestion of contaminated food and 
water. Bacteria are the primary cause of travelers’ diarrhea. In most surveys, the most common 
diarrheal pathogen identified is enterotoxigenic Escherichia coli. There are several antimicrobial 
agents available for the treatment of travelers’ diarrhea including rifaximin which is approved 
in the United States for the treatment of travelers’ diarrhea due to noninvasive E. coli strains. 
In this review, we will review the most recent advances of rifaximin for the treatment and 
prevention of travelers’ diarrhea, with regard to its pharmacokinetics, in vitro susceptibility 
profile, and efficacy and safety data from clinical trials.
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Introduction
Each year, approximately 50 million persons travel internationally from developed 
to developing countries. Although the rates of travelers’ diarrhea vary according to 
the region of the world visited, on average, 40% of travelers will develop traveler’s 
diarrhea.1 Symptoms of clinical illness include passage of profuse and watery 
bowel movements, nausea, bloating, urgency, malaise, flatulence and abdominal 
cramping which typically occur within the first two weeks of travel. Travelers’ 
diarrhea is acquired through the ingestion of contaminated food or water. Food 
items that contain moisture and remain at room temperatures for periods of time 
are of greatest concern.2 The most common cause of food contamination are bacte-
rial agents which are responsible for 80% of cases,3 and the remaining causes are 
parasites and viruses. Enterotoxigenic Escherichia coli (ETEC), enteroaggregative 
E. coli (EAEC), Shigella spp., Salmonella spp., Campylobacter jejuni, Aeromonas 
spp., Plesiomonas spp., and noncholerae Vibrio are the most commonly identified 
bacterial causes of travelers’ diarrhea. There is a subset of travelers who develop 
diarrheal illness without identifiable causes but show improved clinical outcomes 
to antibacterial therapy suggesting that these cases may be due to bacterial agents 
yet to be characterized.4 While travelers’ diarrhea is typically self-limited, illness 
may result in persistent diarrhea in at least 2% of cases, irritable bowel syndrome 
with post-infectious diarrhea in 4%–10% of travelers,5 and other chronic compli-
cations such as reactive arthritis with Salmonella, Shigella, and Campylobacter,6 
and Guillain–Barre syndrome from Campylobacter infection.7 There are several 
antimicrobial agents available for the treatment of travelers’ diarrhea. The treatment Therapeutics and Clinical Risk Management 2009:5 842
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choice is dependent on the country visited by the traveler, the 
targeted coverage of diarrheagenic pathogens, the microbial 
resistance patterns associated with the geographical 
distribution, and the antimicrobial agent’s safety profile 
including limited potential for drug interactions. Rifaximin 
is a poorly absorbed antibacterial agent with an excellent 
safety profile that is effective for travelers’ diarrhea among 
travelers studied in different regions of the world. In this 
review, we will review the most recent advances of rifaximin 
with regard to its pharmacokinetics, in vitro susceptibility 
profile, and efficacy and safety data from clinical trials for 
treatment and chemoprophylaxis of travelers’ diarrhea.
Rifaximin drug class and mechanism 
of action
Rifaximin is a rifamycin derivative with antimicrobial 
activity against a broad spectrum of microorganisms, 
including Gram-positive, Gram-negative, aerobic and 
anaerobic bacteria. The mechanism of its antimicrobial 
activity involves inhibition of bacterial RNA synthesis by 
binding to the beta-subunit of the bacterial DNA-dependent 
RNA polymerase.8
Rifaximin pharmacokinetics
One of the unique properties of rifaximin is its poor oral 
absorption in the human gastrointestinal tract, which 
augments its ability to inhibit replication of enteric 
pathogens with high fecal concentrations while limiting 
the amount of systemic absorption. Adults, with diarrheal 
illness, receiving rifaximin 800 mg per day for three days 
achieve fecal concentrations of rifaximin of approximately 
8000 µg/g.9 Although systemic absorption of rifaximin 
is increased with food intake, less than 0.4% of the drug 
is absorbed from the gastrointestinal tract after oral 
administration. This low systemic absorption is reflected 
by the relatively low maximum drug concentration (Cmax of 
9.63 ng/mL) and area under the concentration time curve 
(AUC of 34.7 ng⋅h/mL) in the fed state. After oral 
administration of 400 mg of C14-rifaximin to healthy 
volunteers, 97% and 0.32% of rifaximin are recovered from 
the feces and the urine unchanged, respectively.8,10–12
Drug interactions with rifaximin are relatively uncommon 
because of its poor oral absorption. Although in vitro studies 
have demonstrated that rifaximin is capable of inducing 
the cytochrome P450 3A4 (CYP3A4) isoenzyme, clinical 
drug–drug interaction studies using midazolam and an oral 
contraceptive containing ethinyl estradiol and norgestimate 
have not demonstrated such an interaction. Rifaximin does 
not significantly affect drugs metabolized by the cytochrome 
P450 isoenzymes.13,14
Since rifaximin is poorly absorbed, no dosage adjust-
ments are necessary for hepatic dysfunction. Among patients 
with liver failure and hepatic encephalopathy who received 
rifaximin 800 mg three times daily for seven days, less than 
0.1% of rifaximin was systemically absorbed.8
Rifaximin in vitro susceptibility
Rifaximin has broad coverage against the diarrheagenic 
pathogens associated with travelers’ diarrhea. Our research 
group evaluated 284 isolates from diarrheal samples from 
travelers to India, Jamaica, Mexico, and Kenya.15 The minimum 
inhibitory concentration that inhibited 90% of microorganism 
growth (MIC90) ranged from 4–64 µg/ml for enterotoxigenic 
(ETEC) and enteroaggregative E. coli (EAEC), Salmonella, 
Shigella, Campylobacter, Plesiomonas, and Aeromonas 
species. These susceptibility patterns have been validated by 
other studies.16,17 However, in an in vitro study of the activity 
of rifaximin against enteropathogens isolated as a cause of 
travelers’ diarrhea among Spanish travelers to developing 
countries, the MIC90 of C. jejuni was 512 µg/ml.18
Although there is concern that resistance to rifaximin 
or cross resistance to rifampin may develop, the high fecal 
concentrations of the drug and limited systemic absorption 
are reasons to believe that the development of resistance and 
cross resistance is unlikely.
The frequency of development of ETEC and EAEC 
rifaximin-resistant mutants were 5.7 × 10-7 -1.6 × 10-6 and 
2.0 × 10-8 -9.3 × 10-8, respectively, by growth on plates 
containing serial dilutions of rifaximin above the bacterial 
MIC.19 In this in vitro study, 26 of 28 mutants exhibited MIC 
levels of 256 mg/L or higher without reversion towards the 
original MIC. Since rifaximin achieves fecal concentrations 
of approximately 8,000 µg/g,9 its effective concentration in 
the gastrointestinal tract is greater than 15–30-fold MIC90 
for these bacterial pathogens and may explain why resistance 
among noninvasive strains of E. coli is uncommonly reported. 
In limited reported cases, resistance to rifaximin among 
Bifidobacterium infantis and Clostridium difficile has been 
associated with mutations in the rpoB gene, which encodes 
for the DNA-dependent RNA polymerase.20,21 However, it has 
not been shown whether these resistance mutations correlate 
with clinical failures. Rifaximin does not induce rifaximin 
or rifampin resistance in Mycobacteria tuberculosis strains 
isolated from humans22 or guinea pigs.23
Despite the high fecal concentrations of rifaximin, the 
medication appears to have surprisingly little effect on the Therapeutics and Clinical Risk Management 2009:5 843
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intestinal microflora. After two weeks of rifaximin, there 
is approximately a 1 log reduction in coliforms per gram 
of stool.24
Efficacy of rifaximin for the 
treatment of travelers’ diarrhea
Rifaximin is approved in the United States and in some Euro-
pean countries for the treatment of patients with travelers’ 
diarrhea caused by noninvasive strains of E. coli among 
patients aged 12 years.8
Several pivotal trials have demonstrated that rifaximin is 
more effective than placebo and as effective as conventional 
antibiotics for the treatment of travelers’ diarrhea (Table 1). 
The predominant pathogens in these trials were E. coli strains, 
including enterotoxigenic (ETEC) and enteroaggregative 
(EAEC) E. coli. These clinical trials were well-designed, 
randomized, double-blind studies which evaluated the 
primary clinical endpoint as the time to last unformed stool 
(TLUS), defined as the time from the administration of the 
first dose to last unformed stool passed, after which clinical 
cure was declared.
Rifaximin was similar in efficacy to trimethoprim-
sulfamethoxazole (TMP-SMX).25 In a randomized, prospec-
tive, double-blind clinical trial including 72 US travelers to 
Mexico, no significant differences in the TLUS were observed 
in a clinical trial comparing five-day courses of rifaximin 
(200 mg, 400 mg, and 600 mg three times a day; [n = 55]) 
and TMP-SMX (160/800 mg two times a day; [n = 17]) 
among travelers to Mexico. There was a trend for shorter 
duration of diarrhea with the administration of rifaximin 200 
mg three times a day. Although not statistically significant, 
clinical failure to respond to treatment occurred in six of 55 
(11%) rifaximin-treated subjects versus five of 17 (29%) 
TMP-SMX-treated subjects.
Rifaximin is similar in efficacy to ciprofloxacin.28 
A randomized, double-blind clinical trial evaluated three 
days of either rifaximin 400 mg twice a day (n = 93) or 
ciprofloxacin 500 mg twice a day (n = 94) as treatment for 
travelers’ diarrhea among travelers to Mexico or Jamaica. The 
principal pathogen identified in this study was enterotoxigenic 
E. coli, occurring in 39% of rifaximin-treated and 38% of 
ciprofloxacin-treated subjects who provided pretreatment 
stool samples. Invasive pathogens were uncommon. 
Rifaximin and ciprofloxacin were comparable in the median 
TLUS (25.7 hours vs 25.0 hours, respectively, P = 0.47) 
and comparable in the clinical cure rate (rifaximin 87% vs 
ciprofloxacin 88%, P = 0.80) and microbiological cure rate 
(rifaximin 74% vs ciprofloxacin 88%, P = 0.22).
Many experts consider ciprofloxacin as the standard 
of treatment for travelers’ diarrhea. However, resistance to 
ciprofloxacin, the most commonly employed fluorquinolone 
for bacterial diarrhea is occurring among bacterial diarrhea-
genic pathogens especially among Campylobacter species in 
areas such as Thailand and other parts of Southern Asia.26,27
A second randomized, double-blind clinical trial 
evaluated 399 travelers with travelers’ diarrhea acquired 
in Mexico, Guatemala, or India.29 Subjects received three 
days of either rifaximin 200 mg three times a day (n = 197), 
placebo (n = 101), or ciprofloxacin 500 mg two times a day 
(n = 101). The principal pathogens identified in this study were 
diarrheagenic E. coli, occurring in 37% of rifaximin-treated 
and 40% of ciprofloxacin-treated subjects. Invasive pathogens 
were uncommon. The median TLUS was shorter for the 
rifaximin group compared to the placebo group (32.0 hours vs 
65.5 hours, P = 0.001) and was similar to the group receiving 
ciprofloxacin (28.8 hours, P = 0.35). A greater percentage of 
rifaximin patients experienced clinical cure (76.6%) com-
pared to subjects receiving placebo (61.4%, P = 0.004) and 
was similar to the ciprofloxacin group (78.2%).
A third randomized, double-blind clinical trial evaluated 
380 travelers with travelers’ diarrhea acquired in Mexico, 
Guatemala, or Kenya.30 Study participants were randomized 
to receive either three days of either rifaximin 200 mg three 
times a day (n = 125) or 400 mg three times a day (n = 126), 
or placebo (n = 129). The median TLUS was significantly 
shorter for both rifaximin groups compared to placebo 
(32.5 hours and 32.9 hours vs 60.0 hours, respectively, 
P = 0.0001). A greater proportion of patients who received 
rifaximin achieved clinical cure compared to the placebo 
group (79.2% and 81.0% vs 60.5%, P = 0.001).
Even when no enteric pathogen was detected in one third 
of patients with travelers’ diarrhea, described as pathogen-
negative travelers’ diarrhea, in a subanalysis from two 
randomized, double-blind, placebo-controlled controlled 
trials, rifaximin was more effective than placebo for median 
TLUS (33 hours vs 68 hours, P  0.005), mean number 
of unformed stools passed (6.5 vs 8.6, P  0.0001), and 
clinical cure (77 vs 61%, P = 0.01).4 These findings suggest 
that pathogen-negative travelers’ diarrhea cases may be due 
to undetected bacterial pathogens yet to be characterized by 
current diagnostic techniques.
Combining rifaximin with loperamide is a very effec-
tive combination for travelers’ diarrhea.31 In a clinical trial, 
310 adults with acute diarrhea were randomized to receive 
rifaximin 200 mg three times daily for three days (n = 102); 
loperamide 4 mg initially followed by 2 mg after each Therapeutics and Clinical Risk Management 2009:5 844
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unformed stool (n = 104); or a combination of both drugs 
using the same dosing regimen (n = 104). The primary end 
point was TLUS. Rifaximin and combination therapy sig-
nificantly reduced the median time until passage of the last 
unformed stool (32.5 hours and 27.3 hours, respectively) 
compared to loperamide alone (69 hours; P = 0.0019). The 
mean number of unformed stools passed during illness was 
lower with combination therapy (3.9) compared with rifaximin 
(6.2; P = 0.004) or loperamide alone (6.7; P = 0.002).
Rifaximin use for invasive enteric 
pathogens
Rifaximin is not approved for the treatment of  travelers’ 
diarrhea associated with invasive enteric pathogens such 
as Shigella species, Campylobacter jejuni, and Salmonella 
species. In a clinical trial comparing the efficacy of rifaximin, 
to placebo and ciprofloxacin for travelers’ diarrhea,29 rifaximin 
was less effective than ciprofloxacin in shortening the duration 
of diarrheal illness and in resolving clinical illness for cases 
caused by invasive enteropathogens. The mean TLUS for three-
day courses of rifaximin 200 mg three times a day, placebo, 
and ciprofloxacin 500 mg two times a day were 33.0 hours, 
65.5 hours, and 28.8 hours, respectively. Median TLUS for 
invasive pathogens was 44 hours for rifaximin, 24 hours for 
ciprofloxacin, and 58 hours for placebo (rifaximin vs placebo; 
P = 0.50). Rifaximin was also evaluated among 13 patients orally 
challenged with Shigella flexneri who developed shigellosis.32 
Eight of these thirteen patients required rescue treatment with 
ciprofloxacin after failing to respond to rifaximin. Rifaximin 
is solely an intraluminal agent and does not appear to be active 
against bacteria invading the gastrointestinal mucosal barrier. 
Therefore, rifaximin is not recommended for patients presenting 
with gastroenteritis complicated by fever or bloody diarrhea.
An option for travelers’ diarrhea and bacterial dysentery 
due to Campylobacter species including ciprofloxacin-resistant 
strains is azithromycin. It has a long half-life and has excellent 
in vitro activity against common bacterial enteric pathogens 
and is effective in Southeast Asia (ie, Thailand and India) 
where fluoroquinolone-resistant Campylobacter species are 
prevalent.27,33 Azithromycin, in a single dose of 500 mg, has 
been found to be comparable to levofloxacin for the treatment 
of US travelers with acute diarrhea acquired in Mexico.34 How-
ever, in this study Campylobacter species were uncommon.
Rifaximin as chemoprophylaxis 
for travelers’ diarrhea
There is an ongoing debate regarding the use of antibacterial 
agents for chemoprophylaxis for travelers’ diarrhea. In the 
past, concerns regarding the promotion of antimicrobial 
resistance and exposure to potential adverse events for a self-
limited disease such as travelers’ diarrhea limited the support 
of antibiotics for the prevention of this illness.35 Widespread 
administration of these drugs may select for resistance and 
limit the future usefulness of these drugs, especially fluo-
roquinolones, for the treatment of life-threatening bacterial 
infections.36 However, with the increased recognition of 
persistent diarrhea and chronic conditions such as irritable 
bowel syndrome among patients after infectious diarrhea,37 
a renewed interest in chemoprophylaxis has arisen.
Rifaximin with its excellent safety profile, lack of drug 
interactions, and minimal effect on the intestinal microbiome 
appears to be an ideal prophylactic drug for travelers’ diar-
rhea especially among travelers to high risk geographic areas 
especially for those who are on tight schedules, have become 
ill in past trips or have underlying comorbidities which may 
result in increased susceptibility. Rifaximin is currently 
being evaluated as a prophylactic antibiotic to prevent the 
acquisition of travelers’ diarrhea.
A number of clinical trials have shown that rifaximin 
is effective as a prophylactic agent for the prevention of 
travelers’ diarrhea.24,38,39 In a randomized, double-blind, 
placebo-controlled trial, 210 US travelers to Mexico 
were evaluated for prevention of travelers’ diarrhea with 
rifaximin.24 Subjects received either rifaximin 200 mg 
once daily (n = 50), rifaximin 200 mg twice daily (n = 52), 
rifaximin 200 mg three times daily (n = 54), or placebo 
(n = 54) for two weeks. In total, 15% of subjects receiving 
rifaximin developed travelers’ diarrhea compared to 54% 
of subjects receiving placebo (P = 0.0001) with a protec-
tion rate against travelers’ diarrhea of 72% for subjects 
receiving rifaximin (P  0.001). All rifaximin doses were 
superior to placebo.
A second randomized, double-blind, placebo-controlled 
prophylaxis trial involving 210 travelers to Mexico compared 
a rifaximin 600 mg daily dose (n = 106) to matching 
placebo (n = 104) for 14 days. Persons receiving rifaximin 
prophylaxis were less likely to develop diarrhea compared 
to those receiving placebo (20% vs 48%, respectively, 
P  0.0001) with a protection rate of 58% against travelers’ 
diarrhea. Traveler’s diarrhea-prevention studies among 
travelers to other geographic regions of the world, where the 
distribution of the enteric pathogens may differ, are neces-
sary to determine whether rifaximin is an effective chemo-
prophylaxis outside Mexico. Additional rifaximin prevention 
trials are in progress or await publication, including a clinical 
trial evaluating Europeans in Thailand.38Therapeutics and Clinical Risk Management 2009:5 845
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Rifaximin may be effective in preventing travelers’ 
diarrhea, even when invasive enteric pathogens are the 
causative agents. It is postulated that rifaximin may be active 
against invasive diarrheagenic pathogens in the gastrointes-
tinal tract prior to mucosal penetration.39 The effectiveness 
of rifaximin as a prophylactic agent against Shigella flexneri 
was evaluated in a randomized, double-blind, placebo-
controlled trial in which 25 healthy adults were experimen-
tally challenged with S. flexneri.40 Subjects received either 
rifaximin 200 mg three times a day or placebo for three days 
prior to the S. flexneri challenge. None of the 15 rifaximin 
subjects developed diarrhea, while six of 10 placebo recipi-
ents developed shigellosis (P = 0.001). High MICs associated 
with invasive enteric infections caused by C. jejuni, may limit 
the effectiveness of rifaximin in some regions of the world 
(ie, Thailand and India).18 More studies are needed to confirm 
whether rifaximin may serve as an appropriate prophylaxis 
against invasive diarrheagenic pathogens.
Off-label uses of rifaximin
Rifaximin has reported success for a variety other gastrointesti-
nal disorders including irritable bowel syndrome,41–43 portal sys-
temic encephalopathy,44,45 small intestinal bowel overgrowth,46,47 
antibiotic-associated diarrhea including Clostridium difficile 
infection,48,49 diverticulitis,50,51 inflammatory bowel disease,52,53 
pouchitis,54,55 and prophylaxis for colonic surgery.56,57
Table 1 Rifaximin clinical trials for the treatment and chemoprophylaxis of travelers’ diarrhea
Study, reference Study location Study design Number of subjects Results
Treatment
DuPont et al4 Mexico Randomized, prospective, 
double-blind
Rifaximin (200 mg, 400 mg, 600 mg 
three times a day [n = 55]) or 
TMP-SMX (160/800 mg two times 
a day [n = 17]) both for five days
Clinical failure: rifaximin  
11% vs TMP-SMX 29%
DuPont et al28 Mexico, Jamaica Randomized, prospective, 
double-blind
Rifaximin (400 mg twice a 
day; [n = 93]) or ciprofloxacin 
(500 mg two times a day; 
[n = 94]) both for three days
TLUS: rifaximin 25.7 h vs 
ciprofloxacin 25.0 h Clinical 
cure: rifaximin  
87% vs ciprofloxacin 88%




Rifaximin (200 mg three times a 
day; [n = 197]), placebo (n = 101) 
or ciprofloxacin (500 mg two times 
a day; [n = 101]) all for three days
TLUS: rifaximin 32.0 h vs 
placebo 65.5 h vs ciprofloxacin 
28.8 h Clinical cure: rifaximin 
76.6% vs placebo 61.4% vs 
ciprofloxacin 78.2%





Rifaximin (200 mg [n = 125], 
400 mg three times a day 
[n = 126]) or placebo (n = 129) 
both for three days
TLUS: rifaximin 200 mg  
32.5 h vs rifaximin 400 mg  
32.9 h vs placebo 60.0 h Clinical 
cure: rifaximin 200 mg 79.2% vs 
rifaximin 400 mg 81.0% vs 
placebo 60.5%
DuPont et al31 Mexico Randomized, prospective, 
double-blind
Rifaximin 200 mg three times daily 
(n = 102) for three days, loperamide 
(n = 104) after each unformed 
stool, rifaximin plus loperamide 
(n = 104) for three days
TLUS: rifaximin plus loperamide 
27.3 h vs rifaximin 32.5 h vs 
loperamide 69 h
Chemoprophylaxis
DuPont24 Mexico Randomized, prospective, 
double-blind
Rifaximin (200 mg once daily 
[n = 50], 200 mg twice daily 
[n = 52], 200 mg three times a day 
[n = 54]) or placebo (n = 54) both 
for 14 days
Developed diarrhea: rifaximin  
15% vs placebo 54%
DuPont38 Mexico Randomized, prospective, 
double-blind
Rifaximin (600 mg once daily 
[n = 106]) or placebo (n = 104) 
both for 14 days
Developed diarrhea: rifaximin  
20% vs placebo 48%
Abbreviations:   TMP-SMX, trimethoprim-sulfamethoxazole;   TLUS, time to last unformed stool; h, hours.Therapeutics and Clinical Risk Management 2009:5 846
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Rifaximin safety profile
The poor oral bioavailability of rifaximin contributes to its 
excellent safety profile and low incidence of adverse events. 
Over 1,000 subjects have enrolled in clinical trials evaluating 
rifaximin for travelers’ diarrhea.24,25,20–30 In all of these studies, 
subjects receiving rifaximin reported similar or less adverse 
events compared to those receiving placebo or the active 
comparator (ciprofloxacin or TMP-SMX), respectively. 
Distinguishing true medication-related side effects from the 
underlying diarrheal illness can be challenging. In clinical 
trials, the most common adverse events associated with 
rifaximin are related to the gastrointestinal tract and include 
flatulence, abdominal pain, tenesmus, fecal urgency, and 
nausea.8 No serious adverse events or deaths were reported 
in clinical trials of rifaximin. Other studies of rifaximin for 
other gastrointestinal disorders confirm that rifaximin is a 
well-tolerated treatment.41,44,52
Rifaximin is currently not approved for use in preg-
nant women or children aged less than 12 years. Although 
rifaximin, with its minimal systemic absorption, may be an 
ideal antidiarrheal agent for pregnant women and children, 
studies in these populations are lacking.8
Summary and recommendations
Travelers’ diarrhea is a common illness among travelers 
from developed to developing countries. Illness develops 
after ingestion of contaminated food and water of which 
the majority are caused by bacterial pathogens such 
as enterotoxigenic E. coli (ETEC). The treatment of 
travelers’ diarrhea is dependent on the country visited by 
the traveler, targeted coverage of diarrheagenic pathogens, 
the microbial resistance patterns associated with the 
geographical distribution, and the antimicrobial agent’s 
safety and efficacy profile. There are many antibiotics that 
have been studied for the treatment of travelers’ diarrhea 
including rifaximin which is indicated for the treatment of 
patients (aged 12 years) with travelers’ diarrhea caused 
by noninvasive strains of E. coli. Rifaximin, a rifamycin 
derivative with activity against a broad spectrum of 
microorganisms, is a poorly absorbed oral agent. Since 
rifaximin is poorly absorbed, drug–drug interactions are 
uncommon and resistance and cross resistance with other 
rifamycins are uncommon. The recommended rifaximin 
dose is one 200 mg tablets taken three times a day for 
three days. Several clinical trials show rifaximin is more 
effective than placebo and as effective as TMP-SMX 
and ciprofloxacin using a primary endpoint of TLUS. 
Combination therapy with rifaximan and loperamide is 
more effective and provides more rapid symptomatic 
resolution of diarrheal illness compared to rifaximin 
alone. Rifaximin is not approved for treatment of travelers’ 
diarrhea complicated by fever or blood in the stool or 
diarrhea due to invasive enteric pathogens. Travelers who 
develop fever or blood in the stool or diarrhea especially 
in areas where fluoroquinolone resistant Campylobacter 
species are prevalent have two options for self-treatment 
of watery diarrhea: take rifaximin and have azithromycin 
reserved for the less common febrile dysentery or take 
azithromycin as the single drug. Although not currently 
indicated, clinical trials show that rifaximin is an effective 
chemoprophylactic agent for the prevention of travelers’ 
diarrhea when compared to placebo. Rifaximin has an 
excellent safety profile because it is poorly absorbed 
from the gastrointestinal tract. Adverse events reported 
from clinical trials were similar or less than those from 
subjects receiving placebo or active comparator cipro-
floxacin or TMP-SMX. The most common adverse events 
associated with rifaximin were related to gastrointestinal 
symptoms such as flatulence, abdominal pain, tenesmus, 
fecal urgency, and nausea that are difficult to distinguish 
from the underlying diarrheal illness. Rifaximin is an 
excellent choice for treatment of travelers’ diarrhea due 
to its favorable pharmacokinetics, in vitro susceptibility 
profile, and efficacy and safety data from clinical trials. 
Although nondiscriminate chemoprophylaxis with anti-
bacterial agents for travelers’ diarrhea is controversial, 
we believe that chemoprophylaxis with rifaximin is use-
ful especially among travelers to high risk geographic 
areas such as Mexico, particularly for those who are on 
tight schedules, have become ill in past trips or have 
underlying comorbidities which may result in increased 
susceptibility. For travelers who develop diarrhea despite 
prophylaxis with rifaximin, we recommend a single 1 g 
dose of azithromycin as empirical therapy especially when 
travel is to Southeast Asia where fluoroquinolone-resistant 
Campylobacter species are prevalent. Ongoing studies and 
continued analysis will clarify the role of rifaximin for 
chemoprophylaxis of travelers’ diarrhea.
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